

Guido Baselli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2506977/publications.pdf>

Version: 2024-02-01

43
papers

2,800
citations

430754

18
h-index

414303

32
g-index

43
all docs

43
docs citations

43
times ranked

7146
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
2	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	1.8	193
3	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. <i>Gut</i> , 2021, 70, 180-193.	6.1	86
4	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 3682.	1.6	85
5	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019, 9, 11585.	1.6	82
6	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 160, 1634-1646.e7.	0.6	82
7	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. <i>Gut</i> , 2020, 69, 1855-1866.	6.1	75
8	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , 2020, 52, 102658.	2.7	71
9	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. <i>Blood Transfusion</i> , 2021, 19, 181-189.	0.3	68
10	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	2.4	66
11	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2017, 131, 1301-1315.	1.8	64
12	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	1.3	43
13	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019, 60, 1144-1153.	2.0	42
14	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	2.0	38
15	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	1.8	38
16	PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020, 40, 1130-1141.	1.9	33
17	Association of ABO blood group and secretor phenotype with severe COVID-19. <i>Transfusion</i> , 2020, 60, 3067-3070.	0.8	32
18	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. <i>Current Pharmaceutical Design</i> , 2019, 24, 4566-4573.	0.9	30

#	ARTICLE	IF	CITATIONS
19	PSD3 downregulation confers protection against fatty liver disease. <i>Nature Metabolism</i> , 2022, 4, 60-75.	5.1	15
20	Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4878.	5.8	12
21	Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. <i>Pathology</i> , 2021, 53, 462-469.	0.3	11
22	Genetic insight into COVID-19-related liver injury. <i>Liver International</i> , 2021, 41, 227-229.	1.9	11
23	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. <i>Cells</i> , 2021, 10, 611.	1.8	11
24	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of <i>Ppp2r1b</i> . <i>Science Translational Medicine</i> , 2022, 14, eabh3831.	5.8	11
25	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemic. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1576-1578.	2.8	10
26	Impact of SARS-CoV-2 infection on the recovery of peripheral blood mononuclear cells by density gradient. <i>Scientific Reports</i> , 2021, 11, 4904.	1.6	10
27	Impact of natural neuromedin-B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , 2020, 95, 167-177.	2.0	7
28	Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology. <i>Journal of Lipid Research</i> , 2019, 60, 7-8.	2.0	6
29	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	1.9	6
30	Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges. <i>Journal of Hepatology</i> , 2019, 71, 849-850.	1.8	5
31	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e109-e110.	1.8	5
32	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020, 73, S13-S14.	1.8	4
33	Interaction between dietary factors and insulin resistance in the pathogenesis of nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2015, 47, e230.	0.4	0
34	Impact of Neuromedin-B receptor variants on iron overload disorders. <i>Digestive and Liver Disease</i> , 2018, 50, 25.	0.4	0
35	Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 19.	0.4	0
36	PS-005-Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease. <i>Journal of Hepatology</i> , 2019, 70, e7-e8.	1.8	0

#	ARTICLE	IF	CITATIONS
37	PS-006-MBOAT7 downregulation induces hepatic lipid accumulation. Journal of Hepatology, 2019, 70, e8.	1.8	0
38	THU-335-FXR rs35724 C & G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. Journal of Hepatology, 2019, 70, e307-e308.	1.8	0
39	FRI-333-ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus. Journal of Hepatology, 2019, 70, e542.	1.8	0
40	Risk of liver disease in first-degree relatives of patients with advanced NAFLD: initial data from an Italian cohort study. Digestive and Liver Disease, 2019, 51, e23.	0.4	0
41	Transcriptomics highlights interleukin-32 a novel biomarker showing higher accuracy in carriers of the pnpla3 i148m variant. Digestive and Liver Disease, 2019, 51, e30-e31.	0.4	0
42	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
43	Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. Blood, 2021, 138, 3176-3176.	0.6	0